Status:

COMPLETED

A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

Lead Sponsor:

Takeda

Conditions:

Hemophilia

Eligibility:

MALE

6+ years

Phase:

NA

Brief Summary

The main aim is to describe how the treatment burden and challenges of participants, relatives, and doctors during regular Factor VIII and Factor IX infusions to treat hemophilia evolve using a virtua...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Male participant over the age of 6 years, with diagnosed Congenital Hemophilia A or B, whatever the severity is
  • Participant under long-term prophylaxis with intravenous Factor VIII or Factor IX infusions
  • Participant (or the legal guardians if participant age \<18 years) able and willing to give written informed consent and to comply with the requirements of the study protocol
  • Participant affiliated to the national social security or beneficiary to such insurance
  • Exclusion criteria:
  • Participant with known or suspected hypersensitivity to virtual-reality based tools
  • Participant with central venous line for the administration of Factor VIII or Factor IX
  • Participant (and the legal guardians if participant age \<18 years) with history of unreliability or non-cooperation (including for completion of self-reported questionnaires)
  • Participant (and the legal guardians if participant age \<18 years) with insufficient comprehension of French language
  • Participant taking part in another clinical trial
  • Participant deprived of his liberty by judicial or administrative order
  • NB: participants with haemophilia A having participated in the test phase of the study could be included in the clinical study itself after a period of 4 months minimum with no use of the virtual-reality based solution.

Exclusion

    Key Trial Info

    Start Date :

    June 23 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 21 2024

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT05437211

    Start Date

    June 23 2023

    End Date

    February 21 2024

    Last Update

    June 5 2025

    Active Locations (6)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (6 locations)

    1

    Centre de Reference Hemophilie Unite D'Hemostase Clinique

    Bron, Auvergne-Rhône-Alpes, France, 69677

    2

    CHU Estaing

    Clermont-Ferrand, Auvergne-Rhône-Alpes, France, 69003

    3

    Hôpital de Hautepierre - Pôle MIRMED

    Strasbourg, Grand Est, France, 7200

    4

    CHU Purpan

    Toulouse, Haute-Garonne, France, 31059

    A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions | DecenTrialz